dc.contributor.author |
Faul, Christoph |
de_DE |
dc.date.accessioned |
2015-03-30T14:18:37Z |
|
dc.date.available |
2015-03-30T14:18:37Z |
|
dc.date.issued |
2014 |
de_DE |
dc.identifier.issn |
0732-183X |
de_DE |
dc.identifier.uri |
http://hdl.handle.net/10900/62409 |
|
dc.language.iso |
en |
en |
dc.publisher |
Amer Soc Clinical Oncology |
de_DE |
dc.relation.uri |
http://dx.doi.org/10.1200/JCO.2014.56.3247 |
de_DE |
dc.rights |
info:eu-repo/semantics/closedAccess |
|
dc.subject.ddc |
610 |
de_DE |
dc.title |
Phase II Trial of the Anti-CD19 Bispecific T Cell-Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia |
de_DE |
dc.type |
Article |
de_DE |
utue.quellen.id |
20150115224006_00006 |
de_DE |
utue.publikation.seiten |
4134-U363 |
de_DE |
utue.personen.roh |
Topp, Max S. |
de_DE |
utue.personen.roh |
Gokbuget, Nicola |
de_DE |
utue.personen.roh |
Zugmaier, Gerhard |
de_DE |
utue.personen.roh |
Klappers, Petra |
de_DE |
utue.personen.roh |
Stelljes, Matthias |
de_DE |
utue.personen.roh |
Neumann, Svenja |
de_DE |
utue.personen.roh |
Viardot, Andreas |
de_DE |
utue.personen.roh |
Marks, Reinhard |
de_DE |
utue.personen.roh |
Diedrich, Helmut |
de_DE |
utue.personen.roh |
Faul, Christoph |
de_DE |
utue.personen.roh |
Reichle, Albrecht |
de_DE |
utue.personen.roh |
Horst, Heinz-August |
de_DE |
utue.personen.roh |
Brueggemann, Monika |
de_DE |
utue.personen.roh |
Wessiepe, Dorothea |
de_DE |
utue.personen.roh |
Holland, Chris |
de_DE |
utue.personen.roh |
Alekar, Shilpa |
de_DE |
utue.personen.roh |
Mergen, Noemi |
de_DE |
utue.personen.roh |
Einsele, Hermann |
de_DE |
utue.personen.roh |
Hoelzer, Dieter |
de_DE |
utue.personen.roh |
Bargou, Ralf C. |
de_DE |
dcterms.isPartOf.ZSTitelID |
Journal of Clinical Oncology |
de_DE |
dcterms.isPartOf.ZS-Issue |
36 |
de_DE |
dcterms.isPartOf.ZS-Volume |
32 |
de_DE |
utue.fakultaet |
04 Medizinische Fakultät |
de_DE |